Bioventus Announces CEO Change

Tony Bihl, CEO of Bioventus, a provider of orthobiologic solutions, is electing to retire on April 30, 2020. As a result, the Bioventus Board of Managers has unanimously appointed Ken Reali, former president and CEO of Clinical Innovations LLC, to assume the role of CEO of Bioventus. Reali will also become a member of the company’s Board of Managers, effective April 20, 2020.
 
Reali served as president and CEO of Clinical Innovations, a medical device company focused in woman’s healthcare, from June 2015 until its successful sale on February 12, 2020. He started his career at Biomet and worked at Stryker, Smith & Nephew, and Baxano Surgical where he held positions of increasing responsibility, including CEO over the past ten years. Reali also worked within the Clinical Therapies business of Smith & Nephew over a decade ago, which was later spun out to become Bioventus. He currently serves on the boards of Ossio Integrative Orthopedics, AdvaMed, and AdvaMed Accel, and is Chairman of the Ethics and Compliance Committee for AdvaMed.
 
“I am honored to have the opportunity to lead Bioventus,” said Reali. “The company’s broad product portfolio, global presence, and solid growth have it well positioned to serve the needs of patients and physicians. Even more successes lie ahead and I’m excited to work with the talented Bioventus team to drive strong value for all stakeholders.”
 
“Tony has been an outstanding CEO and leader of Bioventus and we will miss him, though at the same time, the Board and I are pleased to welcome Ken Reali as the incoming CEO of Bioventus,” said William Hawkins, retired chairman and CEO of Medtronic, Senior Advisor to EW Healthcare, and Bioventus board chairman. “Ken’s experience in business development, driving top and bottom line growth while building a compliant culture, global product commercialization and sales of medical devices, combined with strong background in ethics and compliance, market analysis, experience as a CEO in both public and private companies is just the right fit to lead Bioventus.”
 
“Today I feel great satisfaction with the progress we have made toward achieving our mission and growing Bioventus. We have broadened our product offering, built a talented team, grown revenue and profit each year, and woven together a positive culture focused on the patients we serve,” said Bihl. “I want to thank the Board and my colleagues at this great company and I know Ken Reali will bring new ideas and energy for the next growth phase of Bioventus.“